Patients can live a median of 6.8 years after stage 4 diagnosis

A study of 110 patients at the University of Colorado found that 50% of patients live 6.8 years or longer. These were patients who had access to multiple ALK inhibitors through clinical trials at that research University. That University also used Pemetrexed when patients were given chemotherapy.

However, most of those drugs are now FDA approved in some way or another.

https://www.ncbi.nlm.nih.gov/pubmed/30599201

With the right care, patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis

 

 

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Research. Bookmark the permalink.

Leave a Reply